Regulus Labs, the technology and innovation platform of Regulus Collective, announces a strategic partnership with WeBee to support its expansion into the United States hospitality market.

Novartis has agreed to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen, to bolster its renal disease offerings. The upfront cash payment represents a significant premium over ...

Every investor in Regulus Therapeutics Inc. (NASDAQ:RGLS) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 48% to be precise, ...

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

Regulus Therapeutics has axed 30% of its workforce to conserve cash for its stuttering pipeline. And CEO Paul Grint, M.D., is one of those heading to the exit, having decided to hand in his notice and ...

Regulus Therapeutics Inc. (NASDAQ:RGLS) released topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen (RGLS8429) autosomal dominant polycystic kidney disease ...

Regulus Resources Inc. (“Regulus” or the “Company”, TSX-V: REG, OTCQX: RGLSF) announces that it has adopted a shareholder rights plan (the “Rights Plan”) effective as of March 30, 2026, pursuant to a ...